Study analysis finds Vytorin works better than Lipitor

Share this article:
Merck and Schering-Plough said Monday that new analysis of a previously released study of its jointly marketed Vytorin (ezetimibe/simvastatin) showed it was better at lowering bad cholesterol levels than Pfizer’s top-selling Lipitor (atorvastatin calcium). The study—known as Vytorin Versus Atorvastatin, or Vyva—was presented at the annual scientific meeting of the American College of Cardiology. The new analysis found that a “significantly greater” number of Vytorin users were able to lower their levels of LDL, or “bad cholesterol,” compared with those using Lipitor. Merck and Schering-Plough also said the new analysis showed Vytorin lowered levels of C-reactive protein, or CRP, and apolipoprotein B(1), or Apo B, in a greater percentage of patients than Lipitor. Both CRP and Apo B are believed to be risk markers for cardiovascular disease.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.